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BACTERIOLOGY 
Immunoglobulin G Directed Against 
Toxins A and B of Clostridium 
difficile in the General Population 
and Patients with 
Antibiotic-Associated Diarrhea 
Alfred E. Bacon III and Robert Fekety 
Serum immunoglobulin G (IgG) class antibodies directed 
against toxins A and B of Clostridium difficile were studied 
using an enzyme-linked immunosorbent assay and a serum- 
neutralizing assay based on the MRC-5 tissue cytotoxicity 
assay. Of 185 individuals, 46 sera (24%) in the general popu- 
lation demonstrated IgG antibody, 36 (19.4%) against toxin A 
and 15 (8.1%) against toxin B. Antibody titer in the general 
population did not correlate with serum-neutralizing activity. 
Antibody prevalence fell with age (P = 0.58) over 50 years. 
Six of ten patients with acute primary episodes of C. difficile- 
associated diarrhea demonstrated antibody in convalescent- 
phase sera, predominantly directed against toxin B. Only two 
(28%) of seven patients with a history of relapsing C. difficile 
disease had demonstrable antibody. 
I N T R O D U C T I O N  
The host  immunolog ic  r e sponse  to the toxins of 
Clostridium difficile dur ing  and after episodes  of C. 
difficile-associated diarrhea and  colitis has not  been  
well defined.  In the hamste r  model  of colitis, pro- 
tection with vaccine p repared  individually f rom tox- 
ins A or B a t tenuated  disease. Protect ion was almost 
complete  w h e n  vaccination was pe r fo rmed  with a 
single toxoid der ived from both  A and B (Libby et 
al., 1982). Experience with h u m a n  disease is limited. 
The ability of se rum from patients  with C. difficile 
disease to neutral ize the cytotoxic effects of toxin in 
tissue culture assays has been  demons t ra t ed  (Lish- 
man  et al., 1981; Nakamura  et al., 1981). The rela- 
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t ionship of this serologic response  to disease has not  
been described. 
Serum immunoglobul in  M (IgM) and  IgG anti- 
bodies directed against the toxins of C. difficile have 
been  found  with variable success in h u m a n s  w h e n  
enzyme- l inked immunoso rben t  assay (ELISA) tech- 
niques are used (Aronsson and  Granst rom,  1988; 
Aronsson  et al., 1983; Viscidi et al., 1983). Antibod-  
ies to toxins A and B have been  demons t ra t ed  in the 
sera of >60% of the general  hospital ized adult  pop-  
ulation (Viscidi et al., 1983). There  has been  less 
success demons t r a t i ng  an t ibody  in s tudy ing  the 
nonhosp i t a l i zed  general  popu la t ion  wi th  similar 
techniques but  different antigenic sources (Arons- 
son and Granstrom,  1988; Aronsson  et al., 1983). No 
s tandardized ant ibody assay m e t h o d  has been  rec- 
ognized,  and the antigenic preparat ions  are of dif- 
ferent  source. 
A retrospective evaluat ion of an t ibody response  
suggested that individual  pat ients  with diminished 
IgG ant ibody response  to toxin B were  more  likely to 
deve lop  relapses  of C. difficile (Aronsson  et al., 
1985). The host  immune  response  to its toxins is yet  
to be well investigated. In this s tudy,  a modif ied 
indirect ELISA was used to evaluate the IgG host  
response  to the toxins of C. difficile in pat ients  wi th  
acute C. difficile diarrhea as well as in individuals 
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with a history of relapsing disease. In addition, we 
used the same assay to evaluate the prevalence of C. 
difficile antibody in the general population and com- 
pared this with serum neutralizing activity. 
Our assay uses a very well defined and described 
antigen preparation. In addition, a wide control- 
negative population with strict definition allows for 
its increased specificity as well as sensitivity with 
appropriate cutoffs. 
M A T E R I A L S  A N D  M E T H O D S  
Sera 
Control-positive sera were identified by screening 
sera stored at -70°C from patients with biopsy- 
proven C. difficile colitis. Control-negative sera were 
obtained from individuals with the following crite- 
ria: (a) no history of hospitalization or employment 
in a hospital, (b) no antibiotic use for the preceding 
2 years, (c) no history of diarrhea with antibiotic 
use, and (d) stool negative for C. difficile toxin and 
culture. General population sera were obtained 
from the American Red Cross Blood Bank (Detroit, 
MI, USA). The only information made available was 
the age of the blood donor. Sera from patients with 
primary episodes of C. difficile disease were defined 
as acute phase if obtained within 1 week of toxin- 
positive stool without prior history of disease and 
convalescent thereafter. There were 185 total sera 
from the general population, nine control-negative 
sera, ten patients with acute C. difficile disease, and 
seven patients with relapsing diarrhea studied. 
T o x i n s  
Purified toxin A and homogeneous toxin B of C. 
difficile VPI strain 10463 were provided and prepared 
as previously described (Lyerly et al., 1986). Essen- 
tially both proteins were purified by using ammo- 
nium sulfate precipitation with ion-exchange chro- 
matography. Toxin A was further purified with 
precipitation at pH 5.6 while an immunoabsorption 
chromatography was used to purify toxin B (Lyerly 
et al., 1986). All concentrations were standardized 
with a Biorad protein assay using a ~/-globulin stan- 
dard (Biorad). 
ELISA 
For the indirect ELISA, 96-well polystyrene plates 
(Dynatech, Alexandria, VA, USA) were used. Indi- 
vidual wells were coated with 100 txl of solution of 
toxin A or B in phosphate-buffered saline (PBS, pH 
= 7.4) at concentrations of 0.6 p~g/ml (toxin A) and 
1.0 ~g/ml (toxin B). Optimal concentrations were 
determined by using a modified checkerboard tech- 
nique. Coating was performed at room tempera- 
ture, incubating for 16 h. Plates were then washed 
five times with PBS with 0.05% Tween solution, 
stored dry at 4°C, or used immediately. A total of 
100 t~1 of sera diluted 1/200 in PBS with 0.05% Tween 
and 0.5% Gelatin was added to the wells and incu- 
bated for 1 h at room temperature. Plates were again 
washed five times. A 100-~xl solution of alkaline- 
phospha tase -con juga ted  g o a t - a n t i - h u m a n  IgG 
(Sigma, St. Louis, MO, USA) at a concentration of 
0.22 ~g/ml was then applied and incubated at room 
temperature for 1 h. Plates were again washed five 
times and then developed with 100 }xl of p-nitrophe- 
nyl phosphate substrate (Sigma) at a concentration 
of 5 mg/ml for 60 min with the resulting absorbance 
(Au) at a wavelength of 405 nm being determined 
on a Titertek Multiscan (Flow Laboratories, Costa 
Mesa, CA, USA). 
All sera were run in duplicate and in an uncoated 
well to serve as control. The Au was determined by 
calculating the mean of the Au value in the antigen- 
coated wells minus the Au value of the uncoated 
wells. On each plate, nine control-negative sera 
were run and one control positive. Plates were dis- 
carded if the background activity in the uncoated 
wells was >0.150 Au or if the control-positive serum 
was <1.5 Au (IgG toxin B antibody assay) or <0.3 
Au (IgG toxin A antibody assay). A positive cutoff 
value for antibody (Ab) titer was defined as the 
mean plus 3 standard deviations of the nine control- 
negative sera Au from the same plate. This was de- 
signed to optimize specificity and sensitivity. 
TABLE 1 ELISA Immunoglobulin G Antibody (Ab) versus Toxins A and B in 
the General Population 
17-30 58 14 (24.1) 2 (3.4) --  16 (27.5) 
31-40 48 7 (14.5) 3 (6.2) 3 13 (27.0) 
41-50 37 8 (21.6) 1 (2.2) 1 10 (27.0) 
51-65 42 2 (4.8) 4 (9.5) 1 7 (16.6) a 
Total 185 31 (16.7) 10 (5.4) 5 (2.7) 46 (24.8) 
"P = 0.58. 
Age No. A Ab (%) B Ab (%) A + B Ab Total (%) 
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Neutralizing Assay 
The MRC-5 tissue cytotoxicity assay was used to 
determine serum-neutral izing capacity for both 
toxin A and toxin B. The minimum tissue cytotoxic 
dose (TCD by weight) in 50 ~I of solution (PBS) 
required to destroy 100% of cells in the tissue cul- 
ture wells was defined as the TCD100. Mixed and 
incubated at room temperature for 1/2 h were 50 ~l 
of sera and 50 p,1 of PBS with 4 TCD10 o equivalents• 
Then, 50 ~1 (therefore containing 2 TCD100) was 
then plated onto the MRC-5 tissue culture microtiter 
wells. Serial dilutions of serum 1/5, 1/10, and 1/50 
were performed in PBS (pH 7.2). The maximum di- 
lution capable of inhibiting cytotoxicity was then re- 
corded• 
Statistical Analysis 
Neutralizing activity and serum antibody compari- 
son with age was made by univariant analysis. Chi- 
square was applied to all of the comparable data. 
RESULTS 
General Population Sera 
Serum IgG antibody directed at the toxins of C. dif- 
ficile was d e m o n s t r a t e d  in 46 of the 185 sera 
screened by ELISA (Table 1): 31 (16.7%) had anti- 
body versus toxin A only, 10 (5.4%) toxin B only, 
and 5 (2.7%) both toxins. When separated by age, 
the prevalence of C. difficile toxin antibody in those 
under 50 years of age was -27%. Over the age of 50 
and up to 65 years of age, the prevalence of anti- 
body dropped to 16.6% (P = 0.58). 
A total of 111 sera were studied for toxin-A- or 
B-neutralizing capacity: 18 (16.2%) neutralized toxin 
A, 24 (21.6%) neutralized B, and 8 (7.2%) neutral- 
ized both toxins. There was no correlation between 
ELISA-reactive sera and neutralizing capacity in the 
111 sera run in both assays. Only five of 25 sera 
toxin A antibody ELISA positive neutralized toxin A 
in tissue culture. Of eight toxin B IgG antibody- 
positive sera, six did have neutralizing capacity. As 
Figures 1 and 2 show, there is no correlation with 
titer of ELISA antibody and neutralizing titer. 
Patient Sera 
Ten pa t ien ts  wi th  acute,  p r imary  C. difficile- 
associated diarrhea were  evaluated: eight with 
paired sera and two with convalescent phase only 
(Table 2). Six (60%) demonstrated strong antibody 
titers to toxin B in convalescent sera. Only two 
(20%) had toxin A antibody after disease. Of the 
four patients who failed to mount  antibody to either 
toxin, two were on steroid therapy and one had 
received chemotherapy. No patient developed anti- 
body to toxin A alone. 
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FIGURE 1 Toxin A antibody (Ab) by ELISA immuno- 
globulin G (IgG) compared with neutralizing titer in 
MRC-5 cytotoxicity assay. 
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FIGURE 2 Toxin B antibody (Ab) by ELISA immuno- 
globulin G (IgG) compared with neutralizing titer in 
MRC-5 cytotoxicity assay. 
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TABLE 2 ELISA Immunoglobul in  G Ant ibody (Ab) versus  Toxins A and B in 
Patients with Clostridium difficile Disease a 
Toxin A Ab a Toxin B Ab a 
Patient History Acute ~ Cony b Acute b Convb 
1 Pyelonephritis - -  0.035 - -  0.668( + ) 
2 Pneumonia 0.028 0.403( + ) 0.0 0.853( + ) 
3 Pneumonia 0.008 0.000 0.194 0.339( + ) 
4 Vascular disease - -  0.0071 - -  0.807( + ) 
5 Osteomyelitis 0.010 0.052 0.195 1.750(+) 
6 - -  0 0.150(+) 0.008 0.204(+) 
7 Ulcerative colitis 0.010 0.016 0.050 0 
8 Sepsis 0.057 0.000 0.026 0.058 
9 NHL and CTX c 0.057 0.037 0.126 0.090 
10 COPD d 0 0.045 0.004 0.021 
aELISA antibody in absorbance units (Au). 
bAcute-phase sera K1 week after toxin-positive stool, convalescent-phase sera >1 week after 
toxin positive stool, and (+) denotes titer over "cutoff" ratio = "positive" titer. 
CNon-Hodgkin lymphoma and chemotherapy. 
aChronic obstructive pulmonary disease. 
In addit ion,  seven patients  with a his tory consis- 
tent  with relapsing C. difficile disease were s tudied 
with r a n d o m  serum titers obtained as close to re- 
lapse as possible. These  were  sera referred to the 
Universi ty of Michigan from other  sites after history 
was obta ined and  made  available to us in writing. 
Only  two (28%) of the seven had  demonst rable  an- 
t ibody despi te  mult iple episodes  and  then to toxin B 
(Table 3). 
DISCUSSION 
The ability of the host  to m o u n t  a systemic immune  
response  to the toxins of C. difficile has been  previ- 
ously recognized  (Aronsson and Granstrom,  1988; 
Aronsson  et al., 1983 and 1985; Lishman et al., 1981; 
Viscidi et al., 1983). Early s tudies  u sed  se rum-  
neutral izing capacity (Lishman et al., 1981; Naka- 
mura  et al., 1981) while later investigators focused 
on ELISA technology (Aronsson and  Grans t rom,  
1988; Aronsson  et al., 1983 and 1985; Viscidi et al., 
1983). Variability in assay condit ions,  particularly 
antigenic sources and "cont ro l"  populat ions,  makes  
it difficult to compare  data directly. The results of 
our  s tudy do agree with previously  publ ished data 
in the low prevalence of an t ibody as measu red  by 
ELISA in the general  popula t ion  (Aronsson et al., 
1983). Of interest  is the f inding of lower ant ibody 
prevalence in those individuals over  the age of 50. 
This is the age group most  often no ted  to be at risk 
for the disease. Of individual sera of general  popu-  
lation origin, 27% carry positive ant ibody to C. dif- 
ficile toxins, p redominan t ly  toxin A. Others  have 
noted  a lack of correlation be tween  neutral izing titer 
and ELISA IgG ant ibody except  at high ELISA titers, 
where  they do cor respond (Aronsson et al., 1983; 
Viscidi et al., 1983). Individuals with high neutral-  
izing titer in our  s tudy did not  have positive ELISA 
TABLE 3 ELISA Immunoglobul in  G (IgG) Ant ibody (Ab) in Patients with a 
History of Relapsing Clostridium difficile Disease 
Patient History Sera Date IgG A Ab a IgG B Ab a 
1 AML and CTX b At relapse 0.017 0.059 
2 Six relapses 6 Mo post 0.000 0.117 
3 Mult relapse 3 Days post 0.000 0.007 
4 Mult relapse 2 Mo post 0.016 0.023 
5 Mult relapse Prerelapse 0.010 0.023 
Postrelapse 0.016 1.673(+) 
6 Mult relapse At relapse 0.003 0.000 
7 Mult relapse 1 Mo post 0.263(+) 1.728( + ) 
aELISA antibody expressed as absorbance units (Au). 
bChemotherapy. 
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antibody titers. The possibility exists that antibody 
avidity diminishes with time, or that the assays are 
identifying antibody directed at different portions of 
the toxins and therefore the steric constraints of 
ELISA technique may limit our ability to search for 
the appropriate antibody. This discrepancy war- 
rants further study. 
Of our patients with documented acute primary 
C. difficile-associated disease, 60% were found to 
have significant antibody titers by ELISA. This de- 
gree of seroresponse has been described by others 
(Aronsson et al., 1985). Of the patients without se- 
roconversion, three received immunosuppressive 
therapy prior to the development of diarrhea. Indi- 
viduals receiving steroids, chemotherapy, or with 
underlying diseases leading to immunosuppression 
represent the population most at risk for disease 
with C. difficile. The relationship between the dis- 
ease state and the host response in this group may 
be pertinent to understanding the processes leading 
to relapse or prolonged illness. 
In the seven patients studied with a history of 
relapsing C. difficile colitis, a much lower rate of se- 
ropositivity (28%) was found than in those patients 
with acute disease (60%). This seroprevalence ap- 
proaches that found in the general population; how- 
ever, the two patients who were seropositive had 
antibody directed against toxin B in distinction to 
the general population data, where toxin B antibody 
is unusual (5.4%). It has been suggested that those 
patients who do not develop antibody specifically 
directed at toxin B are at risk for relapse (Aronsson 
et al., 1985). It appears that toxin B is more immu- 
nogenic during natural disease with C. difficile, as all 
our seropositive patients with primary C. difficile 
mounted extremely high titers to toxin B and less 
often converted to toxin A seropositivity. Toxin A, 
considered less cytotoxic by weight, does not ap- 
pear to induce a significant serologic response. It 
should be noted that even our control-positive sera 
had a very low titer by ELISA (0.3 Au). This indi- 
vidual had well-documented neutralizing capacity. 
The ability of immunologic competence against 
the toxins to mediate the disease state has been doc- 
umented in the hamster model of disease (Libby et 
al., 1982). Growing evidence does support  the pos- 
sibility that individuals that relapse with the disease 
may also demonstrate a lowered immune response. 
The issues surrounding relapsing C. difficile disease 
are complex, and the true role of the host response 
is yet to be fully defined. Of particular interest will 
be the length of time after disease where antibody 
titers can be assessed, and the association of those 
titers with relapse as well as severity of primary dis- 
ease or even the association of antibody response to 
treatment options. 
Our ELISA assay is comparable to those previ- 
ously described (Aronsson, et al., 1983 and 1985; 
Viscici et al., 1983). The assay described in this re- 
port, however, has an improved antigen source and 
well-defined control population. The toxin prepara- 
tions represent optimal purity. The use of a large 
control-negative population in our study and stan- 
dardized positive controls improves the specificity 
particularly with the use of nine negative controls 
run on each plate with a cutoff defined as the mean 
plus 3 standard deviations. Our lack of correlation 
between neutralizing capacity and ELISA titer in the 
general population will need further study and sug- 
gests the potential need for additional immunologic 
techniques, where the binding of the toxin to plates 
may not affect the nature of the assay system. 
This work was supported by grant 5R01 AM-21076-06 from 
the National Institute of Arthritis, Diabetes, and Digestive 
and Kidney Diseases. The authors acknowledge the help of Dr. 
David Lyerly and Dr. Tracy Wilkins, who supplied toxins A 
and B for the study. 
REFERENCES 
Aronsson B, Granstrom M (1988) Immunological response 
to Clostridium difficile infection. In Clostridium difficile: 
Its Role in Intestinal Disease. Eds, RR Rolfe and SM 
Finegold. San Diego: Academic, pp 100-111. 
Aronsson B, Granstom M, Mollby R, Nord CE (1983) En- 
zyme-linked immunosorbent assay (ELISA) for anti- 
body to Clostridium difficile toxins in patients with 
pseudomembranous colitis and antibiotic associated 
diarrhea. J Immunol Methods 60:341-350. 
Aronsson B, Granstrom M, Mollby R, Nord CE (1985) 
Serum antibody response to Clostridium difficile toxins 
in patients with Clostridium difficile diarrhea. Infection 
13:3-7. 
Libby JM, Jortner BS, Wilkins TD (1982) Effects of the two 
toxins of Clostridium difficile in antibiotic-associated ce- 
citis in hamsters. Infect Immun 36:822-829. 
Lishman A, A1-Jumaili I, Record C (1981) Antitoxin pro- 
duction in antibiotic-associated colitis. J Clin PathoI 34: 
414-415. 
Lyerly DM, Roberts MD, Phelps CJ, Wilkins TD (1986) 
Purification and characterization of toxins A and B of 
Clostridium difficile. FEMS Microbiol Lett 33:31-35. 
Nakamura S, Mikawa M, Nakashio S, et al. (1981) Isola- 
tion of Clostridium difficile from the feces and the anti- 
body in sera of young and elderly adults. Microbiol Im- 
munol 25:345-351. 
Viscidi R, Laughon BE, Yolken R, et al. (1983) Serum an- 
tibody response to toxins A and B of Clostridium diffi- 
cile. J Infect Dis 148:93-100. 
